A 6-Year Posttreatment Follow-up of Panic Disorder Patients: Treatment With Clonazepam Predicts Lower Recurrence Than Treatment With Paroxetine
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Background: The aim of this study was to identify factors associated with relapse in panic disorder (PD). Methods: This was an observational study conducted in the outpatient clinic of a psychiatric hospital in Rio de Janeiro, Brazil. In a previous study, 120 patients diagnosed as having PD according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria were randomized to receive clonazepam or paroxetine. After 3 years, treatment was discontinued in patients who had achieved remission. These subjects were included in the current study and were followed up for 6 years. The follow-up assessments were made at 1, 2, 3, 5, and 6 years after treatment discontinuation. Assessment included the number of panic attacks per month, Clinical Global Impression–Severity, and other measures. Patients who had initiated psychotherapy or pharmacological treatment because of PD symptoms or who had Clinical Global Impression–Severity scores greater than 1 or panic attacks in the month preceding the assessment were considered relapse cases. Data were collected from January 2003 to August 2012. Results: Eighty-five patients completed the follow-up. Cumulative relapse rates were 50% (n = 33) at 1 year and 89.4% (n = 76) at 6 years. One-year relapse rates were lower in patients previously treated with clonazepam (P = 0.001) compared with those treated with paroxetine. Low 6-year relapse rates were associated with high Hamilton Anxiety Rating Scale scores before treatment (P = 0.016) and previous treatment with clonazepam. Conclusions: Relapse is a frequent problem in PD, and long-term treatment does not protect these patients in the long run. Treatment with clonazepam predicts lower relapse when compared with paroxetine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090 · cited 2×
“Selective serotonin reuptake inhibitors have been prescribed for PD with or without agoraphobia for over a decade and are recommended as first-line treatment for PD on the basis of their favorable safety profile.(15,16) The efficacy and safety profile of the SSRI paroxetine has been demonstrated in the treatment of PD…”
BackgroundMethodBaldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676 · cited 2×
“Selective serotonin reuptake inhibitors have been prescribed for PD with or without agoraphobia for over a decade and are recommended as first-line treatment for PD on the basis of their favorable safety profile.(15,16) The efficacy and safety profile of the SSRI paroxetine has been demonstrated in the treatment of PD…”
BackgroundMethodExtrasynaptic GABA A Receptors: Form, Pharmacology, and Function
Belelli, D., Harrison, N. L., Maguire, J., Macdonald, R. L., Walker, M. C., & Cope, D. W. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3340-09.2009 · Cited by 464
Neurosteroid modulation of synaptic and extrasynaptic GABAA receptors
Herd, M. B., Belelli, D., & Lambert, J. J. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.03.007 · Cited by 206
Vinkers, C. H., & Olivier, B. (2012) · Advances in Pharmacological Sciences · doi:10.1155/2012/416864 · Cited by 195 · cited 1×
“There is abundant evidence in the literature that neurosteroids are endogenous allosteric regulators that interact with GABAA receptors to modulate both tonic (extrasynaptic) and phasic (synaptic) inhibition.(45,49,50) In addition, acute or chronic neurosteroid treatment may change GABAA receptor subunit expression, e…”
BackgroundNeurosteroids: Endogenous allosteric modulators of GABAA receptors
Lambert, J. J., Cooper, M. A., Simmons, R. D. J., Weir, C. J., & Belelli, D. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.08.009 · Cited by 180 · cited 1×
“There is abundant evidence in the literature that neurosteroids are endogenous allosteric regulators that interact with GABAA receptors to modulate both tonic (extrasynaptic) and phasic (synaptic) inhibition.(45,49,50) In addition, acute or chronic neurosteroid treatment may change GABAA receptor subunit expression, e…”
BackgroundRecurrence of anxiety disorders and its predictors
Scholten, W. D., Batelaan, N. M., van Balkom, A. J., WJH. Penninx, B., Smit, J. H., & van Oppen, P. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.10.031 · Cited by 146 · cited 1×
“Age, sex, and psychological treatment did not correlate with relapse rates.(7) Taylor et al(39) followed 274 remitted anxiety disorder patients for 12months and found relapse rates of 33% for any anxiety disorder and 36% for PD.”
BackgroundEvidence-based pharmacotherapy of panic disorder: an update
Batelaan, N. M., Van Balkom, A. J. L. M., & Stein, D. J. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000800 · Cited by 67 · cited 5×
“Psychotherapy could also be administered to decrease the risk of relapse in high-risk patients.(6,32) We hypothesized that patients with more severe PD, more panic attacks, comorbidity with agoraphobia, poor initial response to pharmacological treatment, residual anxiety symptoms after treatment, females, and young pa…”
BackgroundInfluentialUsami, N., Yamamoto, T., Shintani, S., Higaki, Y., Ishikura, S., Patagiri, Y., & Hara, A. (2002) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.25.441 · Cited by 59
Treatment-Resistant Panic Disorder
Bandelow, B., & Rüther, E. (2004) · CNS Spectrums · doi:10.1017/s1092852900022379 · Cited by 57 · cited 1×
“Unau some patients,(3) but true treatment-resistant patients are few.(4,5) Meanwhile, relapse is very common in patients with this anxiety disorder.”
Background
Cited by
Bandelow, B., Allgulander, C., Baldwin, D. S., Costa, D. L. D. C., Denys, D., Dilbaz, N., Domschke, K., Eriksson, E., Fineberg, N. A., Hättenschwiler, J., et al. (2023) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2022.2086295 · Cited by 158
Self-citationRisks and benefits of medications for panic disorder: A comparison of SSRIs and benzodiazepines
Quagliato, L. A., Freire, R. C., & Nardi, A. E. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1429403 · Cited by 62
“pared to antidepressants, even if the effect was very small and close to no difference [60,61].”
BackgroundBenzodiazepines in anxiety disorders: Reassessment of usefulness and safety
Rickels, K., & Moeller, H. J. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2018.1500031 · Cited by 30
“A 6-year post treatment follow-up report of all patients who completed 3 years of treatment before they were tapered of medications showed that patients treated with clonazepam had significantly lower relapse rates than patients who were treated with paroxetine (Freire et al. 2017).”
BackgroundBenzodiazepines, antidepressants and addiction: A plea for conceptual rigor and consistency
Balon, R., Silberman, E. K., Starcevic, V., Cosci, F., Freire, R. C., Nardi, A. E., Rickels, K., & Shader, R. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119878171 · Cited by 7
“There is also evidence of lower relapse rates in panic disorder patients treated with a benzodiazepine (clonazepam) (34.1% after one-year follow-up) compared to those in patients treated with a serotonin reuptake inhibitor (paroxetine) (61.8% after one-year follow-up) (Freire et al., 2017).”
ResultInfluentialSelf-citation
Metadata
- Authors
- Freire, R. C., Amrein, R., Mochcovitch, M. D., Dias, G. P., Machado, S., Versiani, M., Arias-Carrión, O., Carta, M. G., & Nardi, A. E.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2017-08
- Volume
- 37
- Issue
- 4
- Pages
- 429-434
- ISSN
- 0271-0749 (ISSN-L)
- 1533-712X
- OpenAlex
- W2789648188
- Cited by
- 20
- References
- 14
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A 6-Year Posttreatment Follow-up of Panic Disorder Patients: Treatment With Clonazepam Predicts Lower Recurrence Than Treatment With Paroxetine. https://app.cochat.ai/papers/10.1097/jcp.0000000000000740
- The paper
- Freire, R. C., Amrein, R., Mochcovitch, M. D., Dias, G. P., Machado, S., Versiani, M., Arias-Carrión, O., Carta, M. G., & Nardi, A. E. (2017). A 6-Year Posttreatment Follow-up of Panic Disorder Patients: Treatment With Clonazepam Predicts Lower Recurrence Than Treatment With Paroxetine. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000000740
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.